Acrobiosystems Co.,Ltd. (301080.SZ)
| Previous close | 38.63 |
| Open | 38.94 |
| Bid | 42.53 x N/A |
| Ask | 42.54 x N/A |
| Day's range | 39.38 - 42.94 |
| 52-week range | 33.00 - 74.00 |
| Volume | |
| Avg. volume | 2,021,297 |
| Market cap | 5.13B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | 36.85 |
| EPS (TTM) | 1.16 |
| Earnings date | N/A |
| Forward dividend & yield | 1.50 (3.88%) |
| Ex-dividend date | 07 Jun 2023 |
| 1y target est | 62.83 |
PR NewswireACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research
Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conference 2024, and World Organoid Research Day 2024, the company showcased its advancements in the field with ACROBiosystems' Vice President of Corporate Development and Strategy, Rosanna Zhang, elucidating the strategic importance of organoids in practic
PR NewswireACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers
ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of innovative cell and gene therapies.
PR NewswireACROBiosystems launches GM-grade DLL4 Protein to accelerate stem cell manufacturing
ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, recently announces the launch of GMP grade DLL4. GMP grade DLL4 is a recombinant, soluble form of Delta-like Ligand 4, or DLL4, that is one of the few products available on the market manufactured under GMP conditions.
